Are nodal metastases in ovarian cancer chemoresistant lesions? Analysis of nodal involvement in 105 patients treated with preoperative chemotherapy

European Journal of Gynaecological Oncology

Volumn 25, Issue 2, 2004, Pages 169-174

  Morice, P ^a   Joulie, F ^a   Rey, A ^a   Atallah, D ^a   Camatte, S ^a   Pautier, P ^a   Thoury, A ^a   Lhomme C ^a   Duvillard, P ^a   Castaigne, D ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Chemoresistance; Chemotherapy; Nodal involvement; Ovarian cancer; Para aortic lymphadenectomy

Indexed keywords

PACLITAXEL; PLATINUM;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; HUMAN; HYSTERECTOMY; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; OVARY CANCER; PARAAORTIC LYMPH NODE; PELVIS LYMPH NODE; PELVIS LYMPHADENECTOMY; PREOPERATIVE TREATMENT; SALPINGOOOPHORECTOMY; SECOND LOOK SURGERY;

ADENOCARCINOMA, MUCINOUS; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, ENDOMETRIOID; CYSTADENOCARCINOMA, SEROUS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; SECOND-LOOK SURGERY; TREATMENT OUTCOME;

EID: 10744225812     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Griffiths T.C., Parker L.M., Fuller A.F.: "Role of cytoreductive surgical treatment in the management of advanced ovarian cancer". Cancer Treat. Rep., 1979, 63, 235.
2. Michel G., De Iaco P., Castaigne D., El-Hassan M.J., Lobreglio R., Lhommé C. et al.: "Extensive cytoreductive surgery in advanced ovarian carcinoma". Eur. J. Gynaec. Oncol., 1997, 18, 9.
3. Hacker N.F., Berek J.S., Lagasse L.D., Nieberg R.K., Elashoff R.M.: "Primary cytoreductive surgery for epithelial ovarian cancer". Obstet. Gynecol., 1983, 61, 413.
4. Hoskins W.J., McGuire W.P., Brady M.F., Homesley H.D., Creasman W.T., Berman M. et al.: "The effect of the diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma". Am. J. Obstet. Gynecol., 1994, 170, 974.
5. De Poncheville L., Perrotin F., Lefrancq T., Lansac J., Body G.: "Does paraaortic lymphadenectomy have a benefit in the treatment of ovarian cancer that is apparently confined to the ovaries?". Eur. J. Cancer, 2001, 37, 210.
6. Michel G., Morice P., Castaigne D., Leblanc M., Rey A., Duvillard P.: "Lymphatic spread of stage IB/II cervical carcinoma: Anatomy and surgical implications". Obstet. Gynecol., 1998, 91, 360.
7. Morice P., Joulie F., Camatte S., Atallah D., Rouzier R., Pautier P. et al.: "Lymph node involvement in epithelial ovarian cancer: Analysis of 276 pelvic and para-aortic lymphadenectomies and surgical implications". J. Am. Coll. Surg., 2003, 197, 198.
8. Morice P., Brehier-Ollive D., Rey A., Lhommé C., Pautier P., Duvillard P. et al.: "Results of interval debulking surgery in advanced stage ovarian cancer: An exposed-nonexposed study". Ann. Oncol., 2003, 14, 74.
9. Burghardt E., Winter R.: "The effect of chemotherapy on lymph node metastases in ovarian cancer". Baillieres Clin. Obstet. Gynaecol., 1989, 3, 167.
10. Wu P.C., Qu J.Y., Lang J.H., Tang M.Y., Lian L.J.: "Lymph node metastasis of ovarian cancer: a preliminary survey of 74 cases of lymphadenectomy". Am. J. Obstet. Gynecol., 1986, 155, 1103.
11. Wu P.C., Lang J.H., Huang R.L., Qu J.Y., Wang H., Tang M.Y. et al.: "Lymph node metastasis and retroperitoneal lymphadenectomy in ovarian cancer". Baillieres Clin. Obstet. Gynaecol., 1989, 3, 143.
12. Di Re F., Fontanelli R., Raspagliesi F., Di Re E.: "Pelvic and paraaortic lymphadenectomy in cancer of the ovary". Baillieres Clin. Obstet. Gynaecol., 1989, 3, 131.
13. Scarabelli C., Gallo A., Zarrelli A., Visentin C., Campagnutta E.: "Systematic pelvic and para-aortic lymphadenectomy during cytoreductive surgery in advanced ovarian cancer: potential benefit on survival". Gynecol. Oncol., 1995, 56, 328.
14. Baiocchi G., Grosso G., Di Re E., Fontanelli R., Raspagliesi F., Di Re F.: "Systematic pelvic and paraaortic lymphadenectomy at second-look laparotomy for ovarian cancer". Gynecol. Oncol., 1998, 69, 151.
15. Zinzindohoue C., Lujan R., Boulet S., Spirito C., Bobin J.Y.: "Pelvic and para-aortic lymphadenectomy in epithelial ovarian cancer. Report of a series of 86 cases". Ann. Chir., 2000, 125, 163.
16. Kimball R.E., Schlaerth J.B., Kute T.E., Schlaerth A.C., Santoso J., Ballon S.C. et al.: "Flow cytometric analysis of lymph node metastases in advanced ovarian cancer: clinical and biologic significance". Am. J. Obstet. Gynecol., 1997, 176, 1319.
17. Piccart M.J., Bertelsen K., James K., Cassidy J., Mangioni C., Simonsen E. et al.: "Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results". J. Natl. Cancer Inst., 2000, 92, 699.
18. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y. et al.: "Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer". N. Engl. J. Med., 1996, 334, 1.
19. Spirtos N.M., Gross G.M., Freddo J.L., Ballon S.C.: "Cytoreductive surgery in advanced epithelial cancer of the ovary: the impact of aortic and pelvic lymphadenectomy". Gynecol. Oncol., 1995, 56, 345.
20. Di Re F., Baiocchi G., Fontanelli R., Grosso G., Cobellis L., Raspagliesi F. et al.: "Systematic pelvic and paraaortic lymphadenectomy for advanced ovarian cancer: prognostic significance of node metastases". Gynecol. Oncol., 1996, 62, 360.
21. Trimbos J.B., Vergote I., Bolis G., Vermorken J.B., Mangioni C., Madronal C. et al.: "Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant Chemotherapy in Ovarian Neoplasm trial". J. Natl. Cancer Inst., 2003, 95, 113.
22. Onda T., Yoshikawa H., Yasugi T., Mishima M., Nakagawa S., Yamada M. et al.: "Patients with ovarian carcinoma upstaged to stage III after systematic lymphadenectomy have similar survival to Stage I/II patients and superior survival to other stage III patients". Cancer, 1998, 83, 1555.
23. Ho C.M., Chien T.Y., Shih B.Y., Huang S.H.: "Evaluation of complete surgical staging with pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy for improvement of survival in stage I ovarian clear cell carcinoma". Gynecol. Oncol., 2003, 88, 394.